Developing vaccines in the era of genomics: a decade of reverse vaccinology

被引:129
作者
Seib, K. L. [1 ]
Zhao, X. [1 ]
Rappuoli, R. [1 ]
机构
[1] Novartis Vaccines & Diagnost, I-53100 Siena, Italy
关键词
genomics; Neisseria meningitidis; pathogenic Escherichia coli; proteomics; reverse vaccinology; Streptococcus agalactiae; Streptococcus pneumoniae; Streptococcus pyogenes; GROUP-B-STREPTOCOCCUS; PILUS-LIKE STRUCTURES; ESCHERICHIA-COLI; NEXT-GENERATION; UNITED-STATES; FACTOR-H; PNEUMONIAE; IDENTIFICATION; PROTECTION; CANDIDATE;
D O I
10.1111/j.1469-0691.2012.03939.x
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Clin Microbiol Infect 2012; 18 (Suppl. 5): 109116 Abstract Vaccines have a significant impact on public health, and vaccinology in the era of genomics is taking advantage of new technologies to tackle diseases for which vaccine development has so far been unsuccessful. Almost all existing vaccines were developed based on traditional vaccinology methods, which relied on empirical screening of a few candidates at a time, based on known features of the pathogen. However, the ability to sequence a pathogens genome provides access to its entire antigenic repertoire. As such, genomics has catalysed a shift in vaccine development towards sequence-based Reverse Vaccinology approaches, which use high-throughput in silico screening of the entire genome of a pathogen to identify genes that encode proteins with the attributes of good vaccine targets. Furthermore, the increasing availability of genome sequences has led to the development and application of additional technologies to vaccine discovery, including comparative genomics, transcriptomics, proteomics, immunomics and structural genomics. Vaccine candidates identified from a pathogens genome or proteome can then be expressed as recombinant proteins and tested in appropriate in vitro or in vivo models to assess immunogenicity and protection. The process of reverse vaccinology has been applied to several pathogens, including serogroup B Neisseria meningitidis, Streptococcus agalactiae, Streptococcus pyogenes, Streptococcus pneumoniae and pathogenic Escherichia coli, and has provided scores of new candidate antigens for preclinical and clinical investigation. As novel genome-based technologies continue to emerge, it is expected that new vaccines for unmet diseases will be within reach.
引用
收藏
页码:109 / 116
页数:8
相关论文
共 76 条
[1]   Quantitative profile of the uropathogenic Escherichia coli outer membrane proteome during growth in human urine [J].
Alteri, Christopher J. ;
Mobley, Harry L. T. .
INFECTION AND IMMUNITY, 2007, 75 (06) :2679-2688
[2]   ApiDB: integrated resources for the apicomplexan bioinformatics resource center [J].
Aurrecoechea, Cristina ;
Heiges, Mark ;
Wang, Haiming ;
Wang, Zhiming ;
Fischer, Steve ;
Rhodes, Philippa ;
Miller, John ;
Kraemer, Eileen ;
Stoeckert, Christian J., Jr. ;
Roos, David S. ;
Kissinger, Jessica C. .
NUCLEIC ACIDS RESEARCH, 2007, 35 :D427-D430
[3]   A second pilus type in Streptococcus pneumoniae is prevalent in emerging serotypes and mediates adhesion to host cells [J].
Bagnoli, Fabio ;
Moschioni, Monica ;
Donati, Claudio ;
Dimitrovska, Valentina ;
Ferlenghi, Ilaria ;
Facciotti, Claudia ;
Muzzi, Alessandro ;
Giusti, Fabiola ;
Emolo, Carla ;
Sinisi, Antonella ;
Hilleringmann, Markus ;
Pansegrau, Werner ;
Censini, Stefano ;
Rappuoli, Rino ;
Covacci, Antonello ;
Masignani, Vega ;
Barocchi, Michele A. .
JOURNAL OF BACTERIOLOGY, 2008, 190 (15) :5480-5492
[4]   Designing the Next Generation of Vaccines for Global Public Health [J].
Bagnoli, Fabio ;
Baudner, Barbara ;
Mishra, Ravi P. N. ;
Bartolini, Erika ;
Fiaschi, Luigi ;
Mariotti, Paolo ;
Nardi-Dei, Vincenzo ;
Boucher, Phil ;
Rappuoli, Rino .
OMICS-A JOURNAL OF INTEGRATIVE BIOLOGY, 2011, 15 (09) :545-566
[5]  
BAKER CJ, 1981, PEDIATRICS, V68, P544
[6]   Group B streptococcal conjugate vaccines [J].
Baker, CJ ;
Edwards, MS .
ARCHIVES OF DISEASE IN CHILDHOOD, 2003, 88 (05) :375-378
[7]   Distribution and genetic variability of three vaccine components in a panel of strains representative of the diversity of serogroup B meningococcus [J].
Bambini, Stefania ;
Muzzi, Alessandro ;
Olcen, Per ;
Rappuoli, Rino ;
Pizza, Mariagrazia ;
Comanducci, Maurizio .
VACCINE, 2009, 27 (21) :2794-2803
[8]   A pneumococcal pilus influences virulence and host inflammatory responses [J].
Barocchi, MA ;
Rie, J ;
Zogaj, X ;
Hemsley, C ;
Albiger, B ;
Kanth, A ;
Dahlberg, S ;
Fernebro, J ;
Moschioni, M ;
Masignani, V ;
Hultenby, K ;
Taddei, AR ;
Beiter, K ;
Wartha, F ;
von Euler, A ;
Covacci, A ;
Holden, DW ;
Normark, S ;
Rappuoli, R ;
Henriques-Normark, B .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2006, 103 (08) :2857-2862
[9]  
Beeretz I, 2011, 29 ANN M EUR SOC PAE
[10]   Prospects for a group a streptococcal vaccine: Rationale, feasibility, and obstacles - Report of a national institute of allergy and infectious diseases workshop [J].
Bisno, AL ;
Rubin, FA ;
Cleary, PP ;
Dale, JB .
CLINICAL INFECTIOUS DISEASES, 2005, 41 (08) :1150-1156